Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 1, 2005 - Issue 3
Submit an article Journal homepage
161
Views
34
CrossRef citations to date
0
Altmetric
Review

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors

Qing Ma University at Buffalo, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, Buffalo, NY 14260, USA. [email protected]
,
Olanrewaju O Okusanya University at Buffalo, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, Buffalo, NY 14260, USA. [email protected]
,
Patrick F Smith University at Buffalo, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, Buffalo, NY 14260, USA. [email protected]
,
Robert DiCenzo University at Buffalo, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, Buffalo, NY 14260, USA. [email protected]
,
Judianne C Slish University at Buffalo, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, Buffalo, NY 14260, USA. [email protected]
,
Linda M Catanzaro University at Buffalo, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, Buffalo, NY 14260, USA. [email protected]
,
Alan Forrest University at Buffalo, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, Buffalo, NY 14260, USA. [email protected]
&
Gene D Morse University at Buffalo, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, Buffalo, NY 14260, USA. [email protected]
 show all
Pages 473-485 | Published online: 29 Sep 2005

Bibliography

  • SMITH PF, DICENZO R, MORSE GD: Clinical pharmacokinetics of nonnucleoside reverse transcriptase inhibitors. Clin. Pharmacokinet. (2001) 40(12):893–905.
  • SAAG MS: Initiation of antiretroviral therapy: implications of recent findings. Top. HIV Med. (2004) 12(3):83–88.
  • MARTINEZ E, ARNAIZ JA, PODZAMCZER D et al. : Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N. Engl. J. Med. (2003) 349(11):1036–1046.
  • ALLAVENA C, FERRÉ V, BRUNET-FRANÇOIS C et al.: Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. (2005) 39(3):300–306.
  • NEGREDO E, MOLTO J, BURGER D et al.: Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). J. Acquir. Immune Defic. Syndr. (2005) 38(1):47–52.
  • SHELTON MJ, AKBARI B, HEWITT RG, ADAMS JM, MORSE GD: Eradication of Helicobacter pylori is associated with increased exposure to delavirdine in hypochlorhydric HIVpositive patients. J. Acquir. Immune Defic. Syndr. (2000) 24(1):79–82.
  • SHELTON MJ, HEWITT RG, ADAMS JM, COX SR, CHAMBERS JH, MORSE GD: Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. J. Clin. Pharmacol. (2003) 43(2):171–179.
  • MORSE GD, FISCHL MA, SHELTON MJ et al. : Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. (1997) 41(1):169–174.
  • CHAPUT AJ, D’AMBROSIO R, MORSE GD: In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite. Antiviral Res. (1996) 32(2):81–89.
  • SMITH PF, DICENZO R, FORREST A et al.: Population pharmacokinetics of delavirdine and N-delavirdine in HIVinfected individuals. Clin. Pharmacokinet. (2005) 44(1):99–109.
  • DAVEY RT Jr, CHAITT DG, REED GF et al. : Randomized, controlled Phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus Type 1-infected patients. Antimicrob. Agents Chemother. (1996) 40(7):1657–1664.
  • STATON BA, JOHNSON MG, FRIIS JM, ADAMS WJ: Simple, rapid and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma. J. Chromatogr. B. Biomed. Appl. (1995) 668(1):99–106.
  • VON MOLTKE LL, GREENBLATT DJ, GRANDA BW et al. : Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J. Clin. Pharmacol. (2001) 41(1):85–91.
  • TASHIMA KT, CALIENDO AM, AHMAD M et al. : Cerebrospinal fluid human immunodeficiency virus Type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J. Infect. Dis. (1999) 180(3):862–864.
  • MARZOLINI C, TELENTI A, DECOSTERD LA, GREUB G, BIOLLAZ J, BUCLIN T: Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS (2001) 15(1):71–75.
  • VELDKAMP AI, HARRIS M, MONTANER JS et al. : The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus Type 1- infected persons. J. Infect. Dis. (2001) 184(1):37–42.
  • LAMSON MJ, SABO JP, MACGREGOR TR et al. : Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm. Drug Dispos. (1999) 20(6):285–291.
  • HAVLIR D, CHEESEMAN SH, MCLAUGHLIN M et al. : High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J. Infect. Dis. (1995) 171(3):537–545.
  • VAN HEESWIJK RP, VELDKAMP AI, MULDER JW et al. : The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1- infected individuals. AIDS (2000) 14(8):F77–F82.
  • GLYNN SL, YAZDANIAN M: In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J. Pharm. Sci. (1998) 87(3):306–310.
  • ERICKSON DA, MATHER G, TRAGERWF, LEVY RH, KEIRNS JJ: Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P450. Drug Metab. Dispos. (1999) 27(12):1488–1495.
  • RISKA P, LAMSON M, MACGREGOR T et al. : Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab. Dispos. (1999) 27(8):895–901.
  • MURPHY RL: Defining the toxicity profile of nevirapine and other antiretroviral drugs. J. Acquir. Immune Defic. Syndr. (2003) 34(Suppl. 1):S15-S20.
  • WINSTON A, POZNIAK A, SMITH N et al. : Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals? AIDS (2004) 18(3):572–574.
  • CATANZARO LM, SLISH JC, DECENZO R, MORSE GD: Drug interactions with antiretrovirals. Curr. HIV/ AIDS Rep. (2004) 1(2):89–96.
  • TRAN JQ, PETERSEN C, GARRETT M, HEE B, KERR BM: Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. Clin. Pharmacol. Ther. (2002) 72(6):615–626.
  • JUSTESEN US, KLITGAARD NA, BROSEN K, PEDERSEN C: Pharmacokinetic interaction between amprenavir and delavirdine after multipledose administration in healthy volunteers. Br. J. Clin. Pharmacol. (2003) 55(1):100–106.
  • JUSTESEN US, KLITGAARD NA, BROSEN K, PEDERSEN C: Dosedependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers. J. Antimicrob. Chemother. (2004) 54(1):206–210.
  • PRESTON S, PILIERO P, O’MARA E et al.: Evaluation of steady-state interaction between atazanavir and efavirenz. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, US (2002):Abstract 443.
  • WINSTON A, BLOCH M, CARR A et al. : The clinical correlations of trough plasma atazanavir levels in a cohort of HIV-1- positive individuals receiving HAART. 12th Conference on Retroviruses and Opportunistic Infections. Boston, US (2005):Abstract 656.
  • PFISTER M, LABBE L, HAMMER SM et al. : Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob. Agents Chemother. (2003) 47(1):130–137.
  • DUVAL X, LE MOING V, LONGUET C et al. : Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir. Antimicrob. Agents Chemother. (2000) 44(9):2593.
  • GOUJARD C, VINCENT I, MEYNARD JL et al. : Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus Type 1-infected patients. Antimicrob. Agents Chemother. (2003) 47(1):118–123.
  • DEJESUS E, PILIERO P, SUMMERS K et al. : Evaluation of the pharmacokinetic drug interaction between fosamprenavir, fosamprenavir plus ritonavir and nevirapine in HIV-infected patients. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, US (2004):Abstract A447.
  • FELLAY J, MARZOLINI C, DECOSTERD L et al. : Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur. J. Clin. Pharmacol. (2005) 60(12):865–873.
  • WIRE MB, BALLOW C, PRESTON SL et al. : Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS (2004) 18(6):897–907.
  • HSU A, ISAACSON J, BRUN S et al. : Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2003) 47(1):350–359.
  • SOLAS C, POIZOT-MARTIN I, DROGOUL MP et al. : Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br. J. Clin. Pharmacol. (2004) 57(4):436–440.
  • DAILLY E, RELIQUET V, RAFFI F, JOLLIET P: A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients. Eur. J. Clin. Pharmacol. (2005) 61(2):153–156.
  • O’MARA E, AGARWALA S, RANDALL D, GERALDES M, STOLTZ R, MUMMANENI V: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, US (2002):Abstract 444.
  • TACKETT D, CHILD M, AGARWALA S et al. : Atazanavir: a summary of two pharmacokinetic drug interaction studies in healthy subjects. 10th Conference on Retroviruses and Opportunistic Infections. Boston, US (2003):Abstract 543.
  • MORSE GD, ROSENKRANZ S, PARA MF et al. : Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. Antimicrob. Agents Chemother. (2005) 49(8):3373–3381.
  • MA Q, FORREST A, OKUSANYA OO et al. : Pharmacokinetic (PK) interaction studies of efavirenz (EFV) and protease inhibitors (PI) in HIV-seronegative volunteers. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, US (2004):Abstract A459.
  • KUPER JI, D’APRILE M: Drug-drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin. Pharmacokinet. (2000) 39(3):203–214.
  • BORIN MT, CHAMBERS JH, CAREL BJ, GAGNON S, FREIMUTH WW: Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin. Pharmacol. Ther. (1997) 61(5):544–553.
  • BORIN MT, CHAMBERS JH, CAREL BJ, FREIMUTH WW, AKSENTIJEVICH S, PIERGIES AA: Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antiviral Res. (1997) 35(1):53–63.
  • PEDRAL-SAMPAIO DB, ALVES CR, NETTO EM, BRITES C, OLIVEIRA AS, BADARO R: Efficacy and safety of Efavirenz in HIV patients on rifampin for tuberculosis. Braz. J. Infect. Dis. (2004) 8(3):211–216.
  • ROBINSON P, LAMSON M, GIGLIOTTI M, MYERS M: Pharmacokinetic (PK) interaction between nevirapine (NVP) and rifampin (RMP). 12th World AIDS Conference. Geneva, Switzerland (1998):Abstract 60623.
  • OLIVA J, MORENO S, SANZ J et al. : Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis. AIDS (2003) 17(4):637–638.
  • RIBERA E, POU L, LOPEZ RM et al. : Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J. Acquir. Immune Defic. Syndr. (2001) 28(5):450–453.
  • MALDONALDO S, LAMSON M, GIGLIOTTI M, PAV JW, ROBINSON P: Pharmacokinetic (PK) interaction between nevirapine (NVP) and rifabutin (RFB). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, US (1999):Abstract 341.
  • BENEDEK IH, FISKE WD, WHITE SJ, STEVENSON D, JOSEPH JL, KORNHAUSER DM: Pharmacokinetic interaction between multiple doses of efavirenz and rifabutin in healthy volunteers. 36th Annual Meeting of the Infectious Disease Society of America. Denver, US (1998):Abstract 461.
  • EDELSTEIN HE, CUADROS Y: Failure of treatment of tuberculous adenitis due to an unexpected drug interaction with rifabutin and efavirenz. AIDS (2004) 18(12):1748–1749.
  • COX SR, HERMAN BD, BATTS DH, CAREL BJ, CARBERRY PA: Delavirdine and rifabutin: pharmacokinetic evaluation in HIV-1 patients with concentrationtargeting of delavirdine. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, US (1998):Abstract 344.
  • ROBINSON P, GIGLIOTTI M, LAMSON M, AZZAM S, MACGREGOR T: Effect of the reverse transcriptase inhibitor, nevirapine, on the steady-state pharmacokinetics of clarithromycin in HIV-positive patients. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, US (1999):Abstract 374.
  • BENEDEK IH, JOSHI A, FISKE WD et al. : Pharmacokinetic interaction studies in healthy volunteers with efavirenz and the macrolide antibiotics, azithromycin and clarithromycin. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, US (1998):Abstract 347.
  • MICHALETS EL: Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy (1998) 18(1):84–112.
  • BARRETT JS, JOSHI AS, CHAI M, LUDDEN TM, FISKE WD, PIENIASZEK HJ Jr: Population pharmacokinetic meta-analysis with efavirenz. Int. J. Clin. Pharmacol. Ther. (2002) 40(11):507–519.
  • DE MAAT MM, EKHART GC, HUITEMA AD, KOKS CH, MULDER JW, BEIJNEN JH: Drug interactions between antiretroviral drugs and comedicated agents. Clin. Pharmacokinet. (2003) 42(3):223–282.
  • MARTY F, MYLONAKIS E: Antifungal use in HIV infection. Expert Opin. Pharmacother. (2002) 3(2):91–102.
  • PEARSON MM, ROGERS PD, CLEARY JD, CHAPMAN SW: Voriconazole: a new triazole antifungal agent. Ann. Pharmacother. (2003) 37(3):420–432.
  • DONNELLY JP, DE PAUW BE: Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity. Clin. Microbiol. Infect. (2004) 10(Suppl. 1):107–117.
  • FERRARI A, COCCIA CP, BERTOLINI A, STERNIERI E: Methadone - metabolism, pharmacokinetics and interactions. Pharmacol. Res. (2004) 50(6):551–559.
  • ALTICE FL, FRIEDLAND GH, COONEY EL: Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS (1999) 13(8):957–962.
  • HEELON MW, MEADE LB: Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy (1999) 19(4):471–472.
  • OTERO MJ, FUERTES A, SANCHEZ R, LUNA G: Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. AIDS (1999) 13(8):1004–1005.
  • CLARKE SM, MULCAHY FM, TJIA J et al. : Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin. Infect. Dis. (2001) 33(9):1595–1597.
  • STOCKER H, KRUSE G, KRECKEL P et al. : Nevirapine significantly reduces the levels of racemic methadone and (R)- methadone in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2004) 48(11):4148–4153.
  • BOFFITO M, ROSSATI A, REYNOLDS HE, HOGGARD PG, BACK DJ, DI PERRI G: Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment. AIDS Res. Hum. Retroviruses (2002) 18(5):341–342.
  • CLARKE SM, MULCAHY FM, TJIA J et al. : The pharmacokinetics of methadone in HIV-positive patients receiving the nonnucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. (2001) 51(3):213–217.
  • BOOKER B, SMITH P, FORREST A et al. : Lack of effect of methadone (MET) on the pharmacokinetics (PK) of delavirdine (DLV) & N-delavirdine. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, US (2001):Abstract A490.
  • JOHNSON RE, CHUTUAPE MA, STRAIN EC, WALSH SL, STITZER ML, BIGELOW GE: A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med. (2000) 343(18):1290–1297.
  • MCCANCE-KATZ EF, PADE P, FRIEDLAND G, MORSE G, MOODY D, RAINEY P: Efavirenz decreases buprenorphine exposure, but is not associated with opiate withdrawal in opioid dependent individuals. 12th Conference on Retroviruses and Opportunistic Infections. Boston, US (2005):Abstract 653.
  • LIEDTKE MD, LOCKHART SM, RATHBUN RC: Anticonvulsant and antiretroviral interactions. Ann. Pharmacother. (2004) 38(3):482–489.
  • TSENG AL, FOISY MM: Significant interactions with new antiretrovirals and psychotropic drugs. Ann. Pharmacother. (1999) 33(4):461–473.
  • DICENZO R, PETERSON D, CRUTTENDEN K et al. : Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. (2004) 48(11):4328–4331.
  • PENZAK SR, CHUCK SK: Management of protease inhibitor-associated hyperlipidemia. Am. J. Cardiovasc. Drugs (2002) 2(2):91–106.
  • FICHTENBAUM CJ, GERBER JG: Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin. Pharmacokinet. (2002) 41(14):1195–1211.
  • CASTRO JG, GUTIERREZ L: Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. Am. J. Med. (2002) 112(6):505.
  • CARR A, WORKMAN C, CAREY D et al. : No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebocontrolled trial. Lancet (2004) 363(9407):429–438.
  • MILDVAN D, YARRISH R, MARSHAK A et al. : Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J. Acquir. Immune Defic. Syndr. (2002) 29(5):471–477.
  • COHN SE, WATTS D, LERTORA J, PARK JG, YU S: An open-label, nonrandomized study of the effect of depomedroxyprogesterone acetate on the pharmacokinetics (PK) of selected protease inhibitors and non-nucleoside reverse transcriptase inhibitors therapies among HIV-infected women. 12th Conference on Retroviruses and Opportunistic Infections. Boston, US (2005):Abstract 82.
  • SCOTT LJ, PERRY CM: Delavirdine: a review of its use in HIV infection. Drugs (2000) 60(6):1411–1444.
  • ZAPOR MJ, COZZA KL, WYNN GH, WORTMANN GW, ARMSTRONG SC: Antiretrovirals, Part II: focus on nonprotease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). Psychosomatics (2004) 45(6):524–535.
  • WYNN GH, COZZA KL, ZAPOR MJ, WORTMANN GW, ARMSTRONG SC: Med-psych drug-drug interactions update. Antiretrovirals, part III: antiretrovirals and drugs of abuse. Psychosomatics (2005) 46(1):79–87.
  • FAIRFIELD KM, EISENBERG DM, DAVIS RB, LIBMAN H, PHILLIPS RS: Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch. Intern. Med. (1998) 158(20):2257–2264.
  • PISCITELLI SC, BURSTEIN AH, CHAITT D, ALFARO RM, FALLOON J: Indinavir concentrations and St John’s wort. Lancet (2000) 355(9203):547–548.
  • DE MAAT MM, HUITEMA AD, MULDER JW, MEENHORST PL, VAN GORP EC, BEIJNEN JH: Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br. J. Clin. Pharmacol. (2002) 54(4):378–385.
  • HENNESSY M, KELLEHER D, SPIERS JP et al.: St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br. J. Clin. Pharmacol. (2002) 53(1):75–82.
  • PISCITELLI SC, BURSTEIN AH, WELDEN N, GALLICANO KD, FALLOON J: The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin. Infect. Dis. (2002) 34(2):234–238.
  • BACK D, GATTI G, FLETCHER C et al. : Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS (2002) 16(Suppl. 1): S5–S37.
  • GERBER JG, ACOSTA EP: Therapeutic drug monitoring in the treatment of HIVinfection. J. Clin. Virol. (2003) 27(2):117–128.
  • FELLAY J, MARZOLINI C, MEADEN ER et al. : Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 359(9300):30–36.
  • CSAJKA C, MARZOLINI C, FATTINGER K et al. : Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. (2003) 73(1):20–30.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.